
Peijia Medical Limited
9996.HKHKSEHealthcareMedical - Devices
最新資料
HK$5.34
+HK$0.365 · +7.34%
9996.HK公司概覽
盤中時間採用HKT。市場資料可能有所延遲。
公司概況
公司網站Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- CN
- 執行長
- Yi Zhang
- 上市以來
- 2020年5月15日
- 僱員
- 1,022
市場位置
日內區間
目前HK$5.34,
52週區間
目前HK$5.34,
- 開盤價
- HK$5.18
- 前收盤價
- HK$4.975
- 成交量
- 92.4萬
- 0.9× 平均值
- 平均成交量
- 102.4萬
- 日均成交量
- 市值
- 35.75億 HKD
- 貝塔
- 0.59
- 市場參考 1
- 50天平均值
- HK$4.2978
- 高於平均水平+24.25%
- 200天平均值
- HK$5.5673
- 低於平均水平-4.08%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 34.38億 CNY
- 本益比(TTM)
- -15.26×
- 股價淨值比(TTM)
- 1.65×
- 股價營收比(TTM)
- 4.3×
- EV/EBITDA
- -25.69×
- 盈餘收益率
- -5.66%
- 自由現金流收益率
- -9.06%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 68.18%
- 營業利益率
- -27.87%
- 淨利潤率
- -28.52%
- 股東權益報酬率
- -11.02%
- 資產報酬率
- -7.65%
- 投入資本報酬率
- -8.37%
財務健康
- 負債權益比
- 0.24×
- 流動比率
- 1.21×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(CNY) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7.13億 CNY | 6.15億 CNY | 4.41億 CNY | 2.51億 CNY | 1.37億 CNY |
| 銷貨成本 | 2.27億 CNY | 1.82億 CNY | 1.16億 CNY | 7463.2萬 CNY | 4088萬 CNY |
| 毛利 | 4.86億 CNY | 4.34億 CNY | 3.25億 CNY | 1.76億 CNY | 9565.4萬 CNY |
| 研究與開發 | 2.67億 CNY | 2.33億 CNY | 2.93億 CNY | 3.73億 CNY | 4.54億 CNY |
| 銷售、一般及管理費用 | 4.47億 CNY | 4.79億 CNY | 4.67億 CNY | 3.65億 CNY | 2.08億 CNY |
| 營業費用 | 6.85億 CNY | 6.73億 CNY | 7.56億 CNY | 6.19億 CNY | 6.94億 CNY |
| 利息收入 | 780.5萬 CNY | 2248萬 CNY | 3943.7萬 CNY | 4662.9萬 CNY | 2477.1萬 CNY |
| 利息支出 | 1173.4萬 CNY | 473.6萬 CNY | 17.8萬 CNY | 231.6萬 CNY | 18.6萬 CNY |
| 折舊和攤銷 | 6228.8萬 CNY | 5341.1萬 CNY | 4280.2萬 CNY | 3601.4萬 CNY | 2748.6萬 CNY |
| 營業利益 | −1.99億 CNY | −2.39億 CNY | −4.31億 CNY | −4.43億 CNY | −5.99億 CNY |
| 淨利 | −2.03億 CNY | −2.27億 CNY | −3.93億 CNY | −4.08億 CNY | −5.74億 CNY |
公司資料更新於 2026年8月24日。
9996.HK同業公司
持有9996.HK的ETF
報告持有此股票曝險的交易所交易基金。
Dimensional - Emerging Markets Core Equity 2 ETFDFEM21.16萬0.00%94.91億 USD0.39%US$39.93+0.50%
Dimensional World ex U.S. Core Equity 2 ETFDFAX14.13萬0.00%125.66億 USD0.28%US$38.16+0.82%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX13.55萬0.02%6.86億 USD0.65%US$72.22+0.25%
Dimensional - Emerging Core Equity Market ETFDFAE12.52萬0.00%99.95億 USD0.29%US$39.49+0.51%
State Street SPDR Portfolio Emerging Markets ETFSPEM9.61萬0.00%175.73億 USD0.07%US$52.38+0.61%
Dimensional Emerging Markets Sustainability Core 1 ETFDFSE2.97萬0.00%6.38億 USD0.44%US$48.59+0.65%
iShares Neuroscience and Healthcare ETFIBRN2.39萬0.30%792.03萬 USD0.47%US$39.62+0.61%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM- 市場價值
- 21.16萬
- 重量
- 0.00%
- AUM
- 94.91億 USD
- 費用率
- 0.39%
- 價格 / 1日
- US$39.93+0.50%
Dimensional World ex U.S. Core Equity 2 ETFDFAX- 市場價值
- 14.13萬
- 重量
- 0.00%
- AUM
- 125.66億 USD
- 費用率
- 0.28%
- 價格 / 1日
- US$38.16+0.82%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX- 市場價值
- 13.55萬
- 重量
- 0.02%
- AUM
- 6.86億 USD
- 費用率
- 0.65%
- 價格 / 1日
- US$72.22+0.25%
Dimensional - Emerging Core Equity Market ETFDFAE- 市場價值
- 12.52萬
- 重量
- 0.00%
- AUM
- 99.95億 USD
- 費用率
- 0.29%
- 價格 / 1日
- US$39.49+0.51%
State Street SPDR Portfolio Emerging Markets ETFSPEM- 市場價值
- 9.61萬
- 重量
- 0.00%
- AUM
- 175.73億 USD
- 費用率
- 0.07%
- 價格 / 1日
- US$52.38+0.61%
Dimensional Emerging Markets Sustainability Core 1 ETFDFSE- 市場價值
- 2.97萬
- 重量
- 0.00%
- AUM
- 6.38億 USD
- 費用率
- 0.44%
- 價格 / 1日
- US$48.59+0.65%
iShares Neuroscience and Healthcare ETFIBRN- 市場價值
- 2.39萬
- 重量
- 0.30%
- AUM
- 792.03萬 USD
- 費用率
- 0.47%
- 價格 / 1日
- US$39.62+0.61%
繼續GoAI的研究
在 GoAI 中研究9996.HKresearch.disclaimer





